|
| 36658531 | Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. | BMC Nephrol | 2023 |
| 37118383 | Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab. | Clin Pharmacokinet | 2023 |
| 37140706 | Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study. | Adv Ther | 2023 |
| 36493607 | Clinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. | Am J Cardiol | 2023 |
| 35994719 | International Perspectives on the Impact of the COVID-19 Pandemic on Adherence to Prescribed Dual Antiplatelet Therapy: A Window Into Acute Cardiovascular Care. | Crit Pathw Cardiol | 2022 |
| 31599808 | Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. | Ann Surg | 2021 |
| 33518473 | Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. | Arch Cardiovasc Dis | 2021 |
| 33706989 | The Future of Aspirin Therapy in Cardiovascular Disease. | Am J Cardiol | 2021 |
| 33706984 | Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why? | Am J Cardiol | 2021 |
| 33706983 | ISSUE INTRODUCTION: The Diminishing Role of Aspirin in Cardiovascular Medicine: A Special Supplement to The American Journal of Cardiology. | Am J Cardiol | 2021 |
| 33657503 | Higher daily pain severity after emergency department visits is associated with lower return-to-work rates. | Am J Emerg Med | 2021 |
| 33430604 | Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. | Circ Cardiovasc Interv | 2021 |
| 32369396 | Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection. | Am J Respir Crit Care Med | 2020 |
| 33609103 | Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. | Eur Heart J Acute Cardiovasc Care | 2020 |
| 31815570 | Contemporary NSTEMI management: the role of the hospitalist. | Hosp Pract (1995) | 2020 |
| 32014375 | The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. | Am J Emerg Med | 2020 |
| 32984829 | EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report. | Crit Care Explor | 2020 |
| 32947379 | Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. | Crit Pathw Cardiol | 2020 |
| 32750627 | A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus? | Am J Emerg Med | 2020 |
| 30586692 | Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. | Circulation | 2019 |
| 31297231 | Analysis of the symptom response to esomeprazole 20 mg over days 1-4 of a 14-day course of treatment for frequent heartburn: results of two randomised controlled trials. | BMJ Open Gastroenterol | 2019 |
| 31582135 | Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. | J Am Coll Cardiol | 2019 |
| 31579832 | Priority Considerations for Medicinal Cannabis-Related Research. | Cannabis Cannabinoid Res | 2019 |
| 31050868 | Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. | J Thromb Haemost | 2019 |
| 29292694 | Assessing the bioequivalence of over-the-counter esomeprazole banded capsules and multiple-unit pellet system tabletsâ¿©. | Int J Clin Pharmacol Ther | 2018 |
| 30255418 | Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14Â Days of Esomeprazole Treatment. | Adv Ther | 2018 |
| 29895599 | Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. | Circ Cardiovasc Interv | 2018 |
| 30309478 | Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. | J Am Coll Cardiol | 2018 |
| 29524340 | Creation and Implementation of an Outpatient Pathway for Atrial Fibrillation in the Emergency Department Setting: Results of an Expert Panel. | Acad Emerg Med | 2018 |
| 29659797 | Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. | Eur Heart J | 2018 |
| 29788903 | Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20Â mg or placebo for 14Â days: two randomized trials. | BMC Gastroenterol | 2018 |
| 26861858 | Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial. | Angiology | 2017 |
| 28431766 | Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg. | Clin Ther | 2017 |
| 28146465 | Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm. | Pol Arch Intern Med | 2017 |
| 29203195 | 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. | J Am Coll Cardiol | 2017 |
| 29069562 | Dabigatran Reversal with Idarucizumab. | N Engl J Med | 2017 |
| 28598510 | Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. | Clin Cardiol | 2017 |
| 28693366 | Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. | N Engl J Med | 2017 |
| 28893843 | Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). | Circulation | 2017 |
| 27981865 | Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADâ¿¢ study. | J Med Econ | 2017 |
| 25987596 | Coagulation assessment with the new generation of oral anticoagulants. | Emerg Med J | 2016 |
| 26390315 | Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin. | J Med Econ | 2016 |
| 26663474 | Letter to the Editor: Managing Dabigatran-Related Bleeding. | J Intensive Care Med | 2016 |
| 27697437 | Introduction to direct oral anticoagulants and rationale for specific reversal agents. | Am J Emerg Med | 2016 |
| 27697436 | Evidence supporting idarucizumab for the reversal of dabigatran. | Am J Emerg Med | 2016 |
| 27595680 | Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. | Am Heart J | 2016 |
| 27537530 | Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. | Acad Emerg Med | 2016 |
| 27125504 | Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. | Crit Care | 2016 |
| 27331882 | A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction. | Postgrad Med | 2016 |
| 27535290 | Self-Care in the Twenty First Century: A Vital Role for the Pharmacist. | Adv Ther | 2016 |